Jessica Tassan
Stock Analyst at Piper Sandler
(1.02)
# 3,891
Out of 5,157 analysts
86
Total ratings
28.77%
Success rate
-14.52%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jessica Tassan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CI The Cigna Group | Reiterates: Overweight | $374 → $370 | $262.44 | +40.98% | 5 | Mar 3, 2026 | |
| TDOC Teladoc Health | Reiterates: Overweight | $12 → $9 | $5.57 | +61.58% | 7 | Feb 26, 2026 | |
| DOCS Doximity | Maintains: Overweight | $40 → $42 | $24.78 | +69.49% | 6 | Feb 20, 2026 | |
| OMCL Omnicell | Reiterates: Overweight | $63 → $49 | $38.99 | +25.67% | 5 | Feb 6, 2026 | |
| HNGE Hinge Health | Maintains: Overweight | $71 → $60 | $45.97 | +30.52% | 3 | Jan 9, 2026 | |
| ALHC Alignment Healthcare | Maintains: Overweight | $20 → $30 | $18.10 | +65.75% | 6 | Jan 6, 2026 | |
| CVS CVS Health | Reiterates: Overweight | $99 → $101 | $76.32 | +32.34% | 6 | Dec 10, 2025 | |
| OSCR Oscar Health | Upgrades: Overweight | $13 → $25 | $13.30 | +87.97% | 7 | Nov 26, 2025 | |
| UNH UnitedHealth Group | Maintains: Overweight | $423 → $417 | $282.34 | +47.69% | 9 | Oct 29, 2025 | |
| PHR Phreesia | Maintains: Overweight | $33 → $34 | $11.75 | +189.36% | 6 | Sep 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $18 | $3.07 | +486.32% | 4 | Aug 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $8 → $4 | $1.82 | +119.78% | 12 | Aug 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $44 → $86 | $16.33 | +426.64% | 3 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $288 → $272 | $173.62 | +56.66% | 4 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $10 → $8 | $5.40 | +48.15% | 3 | May 23, 2025 |
The Cigna Group
Mar 3, 2026
Reiterates: Overweight
Price Target: $374 → $370
Current: $262.44
Upside: +40.98%
Teladoc Health
Feb 26, 2026
Reiterates: Overweight
Price Target: $12 → $9
Current: $5.57
Upside: +61.58%
Doximity
Feb 20, 2026
Maintains: Overweight
Price Target: $40 → $42
Current: $24.78
Upside: +69.49%
Omnicell
Feb 6, 2026
Reiterates: Overweight
Price Target: $63 → $49
Current: $38.99
Upside: +25.67%
Hinge Health
Jan 9, 2026
Maintains: Overweight
Price Target: $71 → $60
Current: $45.97
Upside: +30.52%
Alignment Healthcare
Jan 6, 2026
Maintains: Overweight
Price Target: $20 → $30
Current: $18.10
Upside: +65.75%
CVS Health
Dec 10, 2025
Reiterates: Overweight
Price Target: $99 → $101
Current: $76.32
Upside: +32.34%
Oscar Health
Nov 26, 2025
Upgrades: Overweight
Price Target: $13 → $25
Current: $13.30
Upside: +87.97%
UnitedHealth Group
Oct 29, 2025
Maintains: Overweight
Price Target: $423 → $417
Current: $282.34
Upside: +47.69%
Phreesia
Sep 5, 2025
Maintains: Overweight
Price Target: $33 → $34
Current: $11.75
Upside: +189.36%
Aug 28, 2025
Maintains: Overweight
Price Target: $16 → $18
Current: $3.07
Upside: +486.32%
Aug 27, 2025
Downgrades: Neutral
Price Target: $8 → $4
Current: $1.82
Upside: +119.78%
Aug 15, 2025
Maintains: Overweight
Price Target: $44 → $86
Current: $16.33
Upside: +426.64%
Jul 31, 2025
Maintains: Neutral
Price Target: $288 → $272
Current: $173.62
Upside: +56.66%
May 23, 2025
Reiterates: Neutral
Price Target: $10 → $8
Current: $5.40
Upside: +48.15%